2409589-21-3
Chemical Structure
Enpatoran dihydrochloride
Synonym(s): M5049 dihydrochloride
- CAS No.: 2409589-21-3
- Formula:C16H17Cl2F3N4
- Molecular Weight:393.23
IUPAC Name: 5-((3R,5S)-3-amino-5-(trifluoromethyl)piperidin-1-yl)quinoline-8-carbonitrile hydrochloride
InChIKey: XXUSUJYZCUAXIE-UVDYRLMLSA-N
SMILES: N#CC1=CC=C(N2C[C@H](C[C@H](C2)N)C(F)(F)F)C3=C1N=CC=C3.Cl.Cl
Biological Activity: Enpatoran dihydrochloride (M5049 dihydrochloride) is an orally active and selective TLR7/8 antagonist. Enpatoran dihydrochloride inhibits the activation of the downstream type I interferon pathway. Enpatoran dihydrochloride is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enpatoran dihydrochloride | Enpatoran dihydrochloride (M5049 dihydrochloride) is an orally active and selective TLR7/8 antagonist. Enpatoran dihydrochloride inhibits the activation of the downstream type I interferon pathway. Enpatoran dihydrochloride is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Morand EF, et al. Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet. Rheumatology. 2026 Jul;8(7):e513-e527.
- [2]. Gaudenzi C, et al. Psoriatic microRNAs induce NK cell activation via an innate immune crosstalk abrogated by the Toll-like receptor 7/8 antagonist Enpatoran. Journal of translational medicine. 2026 Mar 02;24(1):478.
- [3]. Vlach J, et al. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity. The Journal of pharmacology and experimental therapeutics. 2021 Mar;376(3):397-409. [Content Brief]
